Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects.
about
Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and childrenFluticasone versus beclomethasone or budesonide for chronic asthma in adults and childrenPharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via TurbuhalerEvaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug DeliveryPharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects.Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacerCanadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.Survey of adrenal crisis associated with inhaled corticosteroids in the United KingdomMethods to identify drug deposition in the lungs following inhalationDo inhaled corticosteroids inhibit growth in children?Systemic effects of inhaled corticosteroids: an overview.Evaluation of the buccal component of systemic absorption with inhaled fluticasone propionate.Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective.Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitisPharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease.Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease.Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler.Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults.Comparison of the effect of high-dose inhaled budesonide and fluticasone on adrenal function in patients with severe chronic obstructive pulmonary disease.Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease.Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties.Between-Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial.Evaluating the suitability of using rat models for preclinical efficacy and side effects with inhaled corticosteroids nanosuspension formulations.Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung.Delivery of inhaled medication to children.Efficacy and safety of inhaled corticosteroids. New developments.The ISOLDE trial. Side effects with inhaled steroids should not be forgotten.Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children.The problem of dose-response and therapeutic ratio of inhaled steroids.Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects.Exogenous cushing syndrome mimicking human immunodeficiency virus lipodystrophy.Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate.Bioavailability and tolerability of nebulised dexamethasone sodium phosphate in adult horses.Aerosol particle size does not predict pharmacokinetic determined lung dose in children.Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma.Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma.
P2860
Q24243570-101A1F2F-ACA9-4F94-8834-FBDBAD4219F6Q24246921-6F006598-CC68-4DA8-987F-228348FD86ECQ28365894-3A569CBB-9217-4B41-A3E6-0C0DA31868E8Q28396497-E8E2E9AD-BE7D-4281-9105-080AB58E2759Q30430396-FB5DDDAD-5D9D-4FA9-9763-3470CEDD1B5BQ33906322-16E79354-062F-4167-BB02-629046A0B451Q33976334-68CCD68B-079A-4463-8551-D766172757ABQ34161394-FC335A01-C5D9-4DC9-9C01-B878A8646232Q34229278-1D500E84-D9DC-4F4D-914E-66BA0C31BB13Q34345371-E7976019-A0DF-4476-B520-B04723967455Q35056155-2FC80862-6741-401C-8CC7-7D99C5478A57Q35533214-FEB07DB1-EF1A-4F1C-8788-B33102539D19Q35610011-2AC48AB5-AAD7-4C30-8E71-FB521B2F6FD1Q35825224-7C77A4EF-79E8-448D-9A05-FC12A8676FDEQ35825280-25E80E99-8A66-4D1D-8B85-516C9F630A7CQ35841604-93A6CEE2-8B01-4B43-910A-D05F29EBA52BQ36053712-AF39F904-FEE2-4E8F-8BAC-CC85F476E864Q36053825-FCD1A7FE-A2AE-4336-90A3-A6F195F5E20AQ36181507-C58F1FFB-38DE-4AA7-8DCD-DF61A54EC199Q37429593-888C8255-1FB8-4DD2-B86A-FED06E3F092AQ37565681-0B7A892E-A171-4711-B8B0-0580D6D17BD0Q37664466-B95C37DA-9046-473E-AF9F-E49F028C93ABQ41543788-BD04A4D5-4DB4-4D43-8732-B7B47BAF1052Q41597242-5F4C0446-3D8F-43F6-A4EC-6BB57EF699ABQ41680896-8A2A6A22-5982-4CE5-B5F1-B8C20789E6C5Q41728966-06D02494-B811-425B-A4B7-85AB2F80B8E0Q42769541-A7F78906-C4AF-4DEA-A1F2-306B1AA5BA2FQ43043583-A41DB2CB-5083-4ADA-8AC5-A017197B955AQ43636860-EBF843EE-3098-46A2-829C-C4CED669A528Q43836979-5DB20542-3887-410C-AFA2-E799DDD43589Q44119564-12917EE8-80E6-47DE-A89E-50F6D8862767Q44927006-ED966D68-C02F-4BFD-8F0D-2270788F5CB2Q45063551-5425FBE3-D708-4BD9-AB46-4B89085270C2Q46196254-59A551B6-C6F1-4508-A3D1-9927ABAE71E6Q48943114-06192CE1-1D24-4C12-AB87-88304BF11F96Q49083717-5DF4E9EB-338B-4697-930B-38F4034D523A
P2860
Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Pharmacokinetics and systemic ...... ropionate in healthy subjects.
@ast
Pharmacokinetics and systemic ...... ropionate in healthy subjects.
@en
type
label
Pharmacokinetics and systemic ...... ropionate in healthy subjects.
@ast
Pharmacokinetics and systemic ...... ropionate in healthy subjects.
@en
prefLabel
Pharmacokinetics and systemic ...... ropionate in healthy subjects.
@ast
Pharmacokinetics and systemic ...... ropionate in healthy subjects.
@en
P2093
P1476
Pharmacokinetics and systemic ...... ropionate in healthy subjects.
@en
P2093
P304
P356
10.1046/J.1365-2125.1997.D01-1425.X
P407
P577
1997-02-01T00:00:00Z